A New Rapid-Acting Antidepressant

@article{Krystal2020ANR,
  title={A New Rapid-Acting Antidepressant},
  author={John H. Krystal and Dennis S. Charney and Ronald S. Duman},
  journal={Cell},
  year={2020},
  volume={181}
}

Merazin Hydrate Produces Rapid Antidepressant Effects Depending on Activating mTOR Signaling by Upregulating Downstream Synaptic Proteins in the Hippocampus.

The results showed that a single administration of MH was capable of reversing the behavioral defects at 2 h in two classic depressive models including learned helplessness and chronic mild stress, and the rapid antidepressant effect of MH depended on the activation of mTOR to regulate downstream BNDF and synaptic protein expressions.

The Rapid and Long-Lasting Antidepressant Effects of Iridoid Fraction in Gardenia Jasminoides J.Ellis Are Dependent on Activating PKA-CREB Signaling Pathway

GJ-IF is the crucial component in the rapid antidepressant of GJ and was dependent on activating the PKA-CREB signaling pathway, which resulted in rapid and sustained antidepressant effects.

Do Newer Antidepressant Drugs Really Have Reduced Side Effects? Examining a Random “Real World” Sample of 300+ Receivers of Medications

  • Nicholas Adams
  • Psychology
    IAFOR Journal of Psychology & the Behavioral Sciences
  • 2020
Newer antidepressant drugs are frequently cited as having reduced side effect profiles to that of their older counterparts. However, recent studies have begun to dispute this claim, citing selective

Depression in Adolescence and Brain-Derived Neurotrophic Factor

The incidence of depression among adolescents has been rapidly increasing in recent years. Environmental and genetic factors have been identified as important risk factors for adolescent depression.

Orphan G Protein Coupled Receptors in Affective Disorders

This review summarizes in this review how emotional behaviors are modulated by the following oGPCRs: ADGRB2 (BAI2), ADGRG1 (GPR56), GPR3, GPR26,GPR37, Gpr50, G PR52, GRLG1, GPLG2, and GPR61, as well as finding the endogenous ligands for the following GPCRs.

Effects of subanaesthetic S-ketamine on postoperative delirium and cognitive function in elderly patients undergoing non-cardiac thoracic surgery: a protocol for a randomised, double-blinded, placebo-controlled and positive-controlled, non-inferiority trial (SKED trial)

This study aims to evaluate the effect of intraoperative prophylactic S-ketamine compared with that of dexmedetomidine on the incidence of POD in elderly patients undergoing non-cardiac thoracic surgery.

S-Ketamine As An Adjuvant in Patient-controlled Intravenous Analgesia for Prevention of Postpartum Depression: A Randomized Controlled Trial

0.01mg/kg/h S-ketamine as an adjuvant in patient-controlled intravenous analgesia can significantly reduce the incidence of postpartum depression within 14 days and relieve postoperative pain within 48h after cesarean section, without increasing the incidenceof adverse reactions.

S-ketamine as an adjuvant in patient-controlled intravenous analgesia for preventing postpartum depression: a randomized controlled trial

S-ketamine as an adjuvant in PCIA significantly reduces the incidence of PPD within 14 days and relieves pain within 48 h after cesarean delivery, without increasing the rate of adverse reactions.

References

SHOWING 1-9 OF 9 REFERENCES

Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.

The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression, which the agency weighed the drug’s rapid onset and high potential for abuse.

Antidepressant effects of ketamine in depressed patients

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy and is supported by the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.

Continuation of esketamine nasal spray in addition to oral antidepressant treatment resulted in clinically meaningful superiority in delaying relapse compared with antidepressant plus placebo in patients with TRD in stable remission.

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

Preliminary findings indicate that intranasal esketamine compared with placebo, given in addition to comprehensive standard-of-care treatment, may result in significantly rapid improvement in depressive symptoms, including some measures of suicidal ideation, among depressed patients at imminent risk for suicide.

Ketamine Treatment and Global Brain Connectivity in Major Depression

The extent of the functional dysconnectivity identified in MDD and the swift and robust normalization following treatment suggest that GBCr may serve as a treatment response biomarker for the development of rapid acting antidepressants.

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

The results demonstrate that the effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamines.